EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 49 / No 1 (March 2017) J Extra Corpor Technol, 49 1 (2017) 54-58 References
Free Access
Issue
J Extra Corpor Technol
Volume 49, Number 1, March 2017
Page(s) 54 - 58
DOI https://doi.org/10.1051/ject/201749054
Published online 15 March 2017
  1. Extracorporeal Life Support Organization (ELSO) Guidelines for Cardiopulmonary Extracorporeal Life Support. Version 1.3. Published November 2013. Ann Arbor, MI Available at: www.elsonet.org. Accessed December 11, 2016 [Google Scholar]
  2. Lequier L., Annich G., Massicotte P. Anticoagulation and Bleeding in ECLS. Extracorporeal Cardiopulmonary Support in Critical Care (4th ed.). Ann Arbor, MI: ELSO; 2012. [Google Scholar]
  3. Maul T. M., Massicotte M. P., Wearden P. D. ECMO biocompatibility: Surface coatings, anticoagulation, and coagulation monitoring, extracorporeal membrane oxygenation—Advances in therapy, Dr. Michael Firstenberg (Ed.), InTech, 2016 Available at: http://www.intechopen.com/books/extracorporeal-membrane-oxygenation-advances-in-therapy/ecmo-biocompatibility-surface-coatings-anticoagulation-and-coagulation-monitoring [Google Scholar]
  4. Salter B. S., Weiner M. M., Trinh M. A., et al. Heparin-induced thrombocytopenia. A comprehensive clinical review. J Am Coll Cardiol. 2016;67:2519–32. [CrossRef] [PubMed] [Google Scholar]
  5. Greinacher A., Warkentin T. E. Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. Expert Rev Hematol. 2008;1:75–85. [CrossRef] [PubMed] [Google Scholar]
  6. Glick D., Dzierba A. L., Abrams D., et al. Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J Crit Care. 2015;30:1190–4. [CrossRef] [Google Scholar]
  7. Warkentin T. E., Kelton J. G. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–7. [CrossRef] [Google Scholar]
  8. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871–6. [CrossRef] [PubMed] [Google Scholar]
  9. Vonderheide R. H., Thadhani R., Kuter D. J. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med. 1998;105:27–32. [CrossRef] [Google Scholar]
  10. Greinacher A. Heparin-induced thrombocytpenia. N Engl J Med. 2015;373:252–61. [CrossRef] [PubMed] [Google Scholar]
  11. Cuker A., Arepally G., Crowther M. A., et al. The HIT Expert Probability (HEP) Score: A novel pretest probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8:2642–50. [CrossRef] [Google Scholar]
  12. Lillo-Le Louët A., Boutouyrie P., Alhenc-Gelas M., et al. Diagnostic score for heparin induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2014;2:1882–8. [Google Scholar]
  13. Lo G. K., Juhl D., Warkentin T. E., Sigouin C. S., Eichler P., Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65. [CrossRef] [Google Scholar]
  14. Sokolovic M., Pratt A. K., Vukicevic V., Sarumi M., Johnson L. S., Shah N. S. Platelet count trends and prevalence of heparin-induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients. Crit Care Med. 2016;44:e1031–7. [CrossRef] [PubMed] [Google Scholar]
  15. Pappalardo F., Maj G., Scandroglio A., Sampietro F., Zangrillo A., Koster A. Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated. Perfusion. 2009;24:135–7. [CrossRef] [PubMed] [Google Scholar]
  16. Koster A., Huebler S., Potapov E., et al. Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: A single-institution experience in 358 consecutive patients. Ann Thorac Surg. 2007;83:72–6. [CrossRef] [Google Scholar]
  17. Scully M., Gates C., Neave L. How we manage patients with heparin induced thrombocytopenia. Br J Heamtol. 2016;174:9–15. [CrossRef] [Google Scholar]
  18. Francis J. L., Hursting M. J. Effect of argatroban on the activated partial thromboplastin time: A comparison of 21 commercial reagents. Blood Coagul Fibrinolysis. 2005;16:251–7. [CrossRef] [PubMed] [Google Scholar]
  19. Kang M., Alahmadi M., Sawh S., Kovacs M. J., Lazo-Langner A. Fondaparinux for the treatment of suspected heparin induced thrombocytopenia: A propensity score matched study. Blood. 2015;125:924–9. [CrossRef] [PubMed] [Google Scholar]
  20. Linkins L. A., Dans A. L., Moores L. K., et al. Treatment and prevention of heparin-induced thrombocytopenia antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141((Suppl 2)):e495S–530S. [CrossRef] [PubMed] [Google Scholar]
  21. Schwartz J., Padmanabhan A., Aqui N., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: The seventh special issue. J Clin Apher. 2016;31:149–62. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.